The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A recent single-center study demonstrated a 4.28-fold (95% CI, 1.62-11.29) increased risk of NAION with semaglutide relative to non-GLP-1RAs.
“A recent single-center study demonstrated a 4.28-fold (95% CI, 1.62-11.29) increased risk of NAION with semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), relative to non–GLP-1RAs.”
From Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (2025) · cites this paper as [5]
The Letter to the Editor describes Hathaway’s study as single-site and says it reported an association between semaglutide and NAION. It does not give the claimed 4.28-fold estimate or its confidence interval. The letter’s own matched analyses found no significant increase in NAION risk, so those numbers cannot be attributed to its results. (LLM, conf=0.88)
Experimental — accuracy not yet measuredTwo prior studies have investigated NAION and semaglutide and have found contradictory findings.
“Two prior studies4,5 have investigated NAION and semaglutide and have found contradictory findings.”
From Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (2025) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating causal effects from epidemiological data
Hernán, M. Á., & Robins, J. M. (2006) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2004.029496 · Cited by 1,029
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318
Karim, M. E. (2024) · The American Statistician · doi:10.1080/00031305.2024.2368794 · Cited by 14
Flagged first, then by citations
Cited by
Sorted by citations
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, C. X., Hribar, M., Baxter, S., Goetz, K., Swaminathan, S. S., Flowers, A., Brown, E. N., Toy, B., Xu, B., Chen, J., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.6555 · Cited by 129
Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16316 · Cited by 85
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Tesfaye, H., Paik, J. M., Wexler, D. J., Carreno-Galeano, J. T., Yu, E. W.-Y., Freedman, A., Rizzo, J. F., & Patorno, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70200 · Cited by 23
Feldman-Billard, S. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101664 · Cited by 12
de Sousa, É., Sparks, L. M., & Townsend, K. L. (2025) · Diabetes · doi:10.2337/db25-0158 · Cited by 13
Glucagon-like peptide-1 receptor agonists and the eye
Zhang, D. L., & Finn, A. P. (2025) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001137 · Cited by 12
Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy
Abdelaal, A., Serhan, H. A. A., Alsaadi, M., Yaldo, L. M., Gaier, E. D., & Elhusseiny, A. M. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.02.013 · Cited by 9
Maceroni, M., Sasso, P., Giarletti, M., Bruno, V., & Minnella, A. M. (2025) · European Journal of Ophthalmology · doi:10.1177/11206721251331655 · Cited by 8
Özbek, L., Güldan, M., Fidan, D. G., Abdel‐Rahman, S. M., & Kanbay, M. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.05.011 · Cited by 9
Noh, Y., Yin, H., Ghezala, I. B., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2026) · Diabetes Care · doi:10.2337/dc25-2577 · Cited by 8
Conflicting Results—Need for More Transparent and Reproducible Research
Cai, C. X., Hribar, M. R., & Nishimura, A. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0350 · Cited by 8
Lieberman, R. A., Korona-Bailey, J., Banaag, A. L., Fuhrman, B. J., Corrado, R., & Koehlmoos, T. P. (2025) · Military Medicine · doi:10.1093/milmed/usaf522 · Cited by 8
BBiomed, Z. L., Raveendran, D., Fourlanos, S., & Chong, E. W. T. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.12.022 · Cited by 9
DeParis, S. W., Oke, I., Gaier, E. D., Moss, H. E., MacIntosh, P. W., Gilbert, A. L., Dinkin, M., & Chen, J. J. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.04.008 · Cited by 8
Nadeem, N., Issa, R. M. A., Shah, A., Wardeh, R., Rashid, F., Abdelgadir, E., & Bashier, A. M. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.07.002 · Cited by 7
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review
Ramos, R. A. H., Ortiz, M., Krieger, S. D., & Secades, D. (2025) · Cureus · doi:10.7759/cureus.89656 · Cited by 7
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 7
A real-world population-based study on the association between cataracts and antipsychotics
Lakhani, M., Kwan, A. T. H., Chaudry, E., Popovic, M. M., Xie, J. S., Rai, A., Rai, A. S., Margolin, E., & McIntyre, R. S. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.05.021 · Cited by 6
Are synthetic incretins associated with ischaemic optic neuropathy?
Gregory, V., & Mollan, S. P. (2025) · Eye · doi:10.1038/s41433-025-03718-0 · Cited by 6
Vilsbøll, T., Kumar, D. A., Aiello, L. P., Rönnbäck, C., Stellfeld, M., & Larsen, L. M. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328729 · Cited by 7
Chrzanowski, J., Walicka, M., Burzyński, J., Zaraś, M., Michalak, A., & Fendler, W. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005064 · Cited by 6
GLP-1 RAs and Nonarteritic Anterior Ischemic Optic Neuropathy—Making Sense of the Data
Etminan, M., Sodhi, M., & Maberley, D. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.6181 · Cited by 6
Goldenberg, R., Aronson, R., & Trinacty, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70013 · Cited by 5
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 5
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 4
Bloomgarden, Z. T. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70085 · Cited by 3
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 2
Varghese, D., Abdelsalam, D., Ibrahim, S., Lee, A. G., & Bhatti, M. T. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.01.001 · Cited by 2
Semaglutide and Risk of NAION—Additional Insights
Rizzo, J. F., & Carreno-Galeano, J. T. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0005 · Cited by 2
Association of Semaglutide and NAION Reviewed
Klonoff, D. C., & Gombar, S. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1823 · Cited by 1
Self-citationBarnett, M. J., Ibe, F. O., & Lam, J. (2026) · Cureus · doi:10.7759/cureus.100953 · Cited by 1
The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations
Lampsas, S., Chardalia, G.-M., Agapitou, C., Papastamopoulos, K., Theodossiadis, P., Siasos, G., Oikonomou, E., Lambadiari, V., & Chatziralli, I. (2026) · Biomedicines · doi:10.3390/biomedicines14051057 · Cited by 2
Lampsas, S., Agapitou, C., Oikonomou, E., Siasos, G., Theodossiadis, P., Tsivgoulis, G. K., Lambadiari, V., & Chatziralli, I. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07291-4 · Cited by 2
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
Ueda, P., Svanström, H., Söderling, J. K., Pazzagli, L., Wintzell, V., Eliasson, B., Hviid, A. P., & Pasternak, B. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-02096 · Cited by 2
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
“…indicating a possible risk of non-arteritic anterior ischemic optic neuropathy (NAION) after the administration of semaglutide (Chou et al., 2024; Klonoff et al., 2024; Grauslund et al., 2026; Simonsen et al., 2024), the EMA Pharmacovigilance Risk Assessment Committee (PRAC) started a review of…”
Glucagon-like Peptide 1 Receptor Agonist: Balancing Alarm and Caution
Ziemssen, F., Hammes, H., & Helbig, H. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2369-9085
Dziewierz, A., & Siudak, Z. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70128
Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane
Chen, P.-H., Abood, S., & Bloom, S. H. (2025) · Microvascular Research · doi:10.1016/j.mvr.2025.104880 · Cited by 1
Semaglutide and the Effects of Glucagon-like Peptide-1 on Vision
Rajput, R., Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., & Rajput, S. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_25
Sharma, A., Wu, L., Bloom, S., Stanga, P. E., Cai, C. X., Singh, R. P., Verghese, S., Chandrakanth, P., Prabha, D., & Rezaei, K. A. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20260114-01
Maideen, N. M. P., Rashid, S. A., Balasubramanian, R., & Amirthalingam, P. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2659_25
Danesh-Meyer, H. V., & Rizzo, J. F. (2026) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70096
Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy
Reynolds, K. R., O’Malley, K. M., Roy, J. A., & Dave, C. V. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00860
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Lee, J. J., Brothers, T. N., Kim, L. A., Ward, K. E., Yusuf, H., & Wen, X. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.08.029
Sun, H., Xin, X., Yan, J., & Huang, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71358
The eye in the era of GLP-1 receptor agonists ‒ a narrative review of current evidence
Rusinek, H., Korniluk, J., Milusz, N., Dmoch, W., & Maciejewicz, P. (2026) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2026.3.8
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Ueda, P. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70170
Metadata
- Authors
- Klonoff, D. C., Hui, G., & Gombar, S.
- Affiliations
- San Mateo Medical Center (US)
- Atropos Health, Palo Alto, CA, USA
- Stanford Medicine (US)
- Corresponding author
- Klonoff, David C.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2024-07-30
- Volume
- 18
- Issue
- 6
- Pages
- 1517-1518
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC11529103
- OpenAlex
- W4401191418
- Cited by
- 49
- References
- 5
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 1
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- nonarteritic anterior ischemic optic neuropathy, semaglutide, drug safety, real-world evidence, type 2 diabetes, GLP-1 receptor agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
